Christina S. Chu, MD, joins the department of surgical oncology and the gynecologic cancer treatment team after completing her medical residency in obstetrics and gynecology and her fellowship in gynecologic oncology at the Hospital of the University of Pennsylvania. Chu’s interests include clinical trials for ovarian, endometrial, and cervical cancers, with a research focus on cancer immunotherapies, as well as weight-loss interventions for women with endometrial cancer or endometrial hyperplasia. She earned her MD from the University of Pennsylvania School of Medicine.
Stephen C. Rubin, MD, is the new Paul Grotzinger and Wilbur Raab Chair in Surgical Oncology and chief of gynecologic oncology. Nationally regarded for his expertise in the treatment of gynecologic cancers, Rubin specializes in both surgery and chemotherapy to treat patients with ovarian, uterine, cervical, and endometrial cancers, as well as surgery for complex benign gynecologic conditions. He has a special interest in ovarian cancer clinical trials and his research focuses on hereditary ovarian cancer. He earned his MD from the University of Pennsylvania, where he did his residency and fellowship, and later returned to Penn as chief of gynecologic oncology and director of the gynecologic oncology research program at the Abramson Cancer Center.
Stefan K. Barta, MD, MS, MRCP (UK), joins the medical oncology department and hematologic oncology treatment team as an assistant professor. Barta’s research focuses on HIV-related lymphomas, bone marrow transplantation for HIV-positive patients, immunotherapies for lymphoid malignancies, and high-dose chemotherapy for hematologic cancers. He earned his MD from Johann Wolfgang Goethe-University in Frankfurt, Germany, and his MS from Albert Einstein College of Medicine of Yeshiva University in New York, where he also completed his hematologic oncology fellowship. He completed residencies at St. Bartholomew’s and the Royal London School of Medicine in London, as well as St. Luke’s Roosevelt Hospital Center in New York.
Patricia L. Kropf, MD, director of the Fox Chase-Temple myelodysplastic syndrome program and assistant director of the Fox Chase-Temple bone marrow transplant program, joins the hematologic care team of Fox Chase’s medical oncology department. Her clinical research focuses on the use of epigenetic therapy and novel drug combinations to treat myelodysplastic syndromes and acute leukemia. Kropf received her MD from Georgetown University School of Medicine and completed a residency in internal medicine and a fellowship in hematology and oncology at the University of Pittsburgh School of Medicine.
Mary Ellen Martin, MD, FACP, also a member of the Fox Chase-Temple bone marrow transplant program, joins Fox Chase’s department of medical oncology as an associate professor. Her clinical interests include the care and management of patients with acute myeloid leukemia, secondary leukemia, myelodysplastic syndromes, and lymphoblastic lymphoma, as well as bone marrow and stem cell transplantation for these conditions. Martin earned her MD at SUNY Health Science Center at Brooklyn and completed her internal medicine residency at Washington University School of Medicine/Barnes-Jewish Hospital in St. Louis. At the University of Pennsylvania, she completed a fellowship in hematologic oncology and a postdoctoral fellowship studying the Mixed Lineage Leukemia (MLL) gene in acute and secondary leukemias.
Rohit Kumar, MD, an interventional pulmonologist with a special interest in lung cancer screening, joins the department of pulmonary medicine as an attending physician. He earned his MD from the University College of Medical Sciences of the University of Delhi, India, and was a medical resident at the University’s Vallabhbhai Patel Chest Institute. Kumar also completed a residency in internal medicine at the Graduate Hospital of Drexel University and a fellowship in pulmonary, allergy, and critical care at the Hospital of the University of Pennsylvania.